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Abstract
Aim: To increase awareness of possible pitfalls in the design and analysis of a multi-centre
randomized clinical trial and to give an overview of alternative study designs and their consequences
for power analyses in case of limited availability of trial participants.
Methods: Investigation of the assumptions in the power calculation and re-analysis of the original
data of a ‘failed’ trial on the effect of dexamethasone on the duration of mechanical ventilation in
young children with respiratory syncytial virus infection. Use of ‘boundaries approach’ is explored
using the data from this trial. A comprehensive overview of the various modern solutions for the
design of a subsequent trial in this ﬁeld is given.
Results: Two frequent major deﬁciencies of trial design and data analysis are reviewed in depth, i.e.
too optimistic assumptions for the sample size calculation and failure to adjust for centre effects.
Conclusion: Critical review of trial assumptions and if necessary sample size recalculation based on an internal
pilot by a data monitoring committee is recommended to maximize the probability of obtaining conclusive
results.
INTRODUCTION
Just as analytic reports of notable patient cases can provide
insight into the pathophysiology of a disease or lead to the
recognition of side-effects of a drug (1), the report of a single
clinical trial can provide insight into methodological issues
that may not be obvious at first sight. In this paper we use the
information from a single randomized clinical trial (RCT) to
discuss methodological issues that may not be obvious at
first sight, but may have serious implications for the useful-
ness of the results of the trial in clinical practice, and may
guide future study design in this field.
The case came to our attention through our methodology-
consultation service in the Emma Children’s Hospital
(ECH). We think that this trial on the management of venti-
lated infants with respiratory syncytial virus (RSV) infection
is a case in point for many other trials with comparable chal-
lenges, both in paediatrics and in other medical specialties.
We will only pay attention to medical details as far as is
necessary to understand the methodological issues.
Case: From December 1997 to March 2001, data were
collected for a multi-centre randomized placebo-controlled
trial in the Netherlands to evaluate the efficacy of intra-
venous dexamethasone in young patients mechanically ven-
tilated for respiratory syncytial virus lower respiratory tract
infection (RSV-LRTI) (2). Randomization was stratified by
centre. The number of patients to be included was calcu-
lated based on the notion that a between groups reduction
in duration of mechanical ventilation of 1.5 days was clini-
cally relevant and on an estimated Standard Deviation (SD)
of the mean duration of ventilation of 2 days. This calcula-
tion, setting the type I error rate (α) at 5% and the type II
error rate (β) at 20% (i.e. power 80%), resulted in a required
sample size of two groups of 30 patients. However, although
the number of included patients who eventually completed
the trial (n = 82) was sufficient, and the mean difference be-
tween the placebo group and the dexamethasone group was
deemed clinically relevant (1.6 days), the 95% Confidence
Interval (95% CI) was not narrow enough to reach statisti-
cal significance (−0.8 to 3.8 days) (2). This 95% CI indicates
that dexamethasone may reduce the duration of mechanical
ventilation with almost 4 days or it may extend its duration
with almost 1 day. It means that, although the difference
is not statistically significant, the possibility of a clinically
relevant beneficial effect of dexamethasone has not been ex-
cluded. This result could be described as ‘no evidence of
effect’ (3). And so, in spite of an apparently adequate power
calculation, the trial did not yield results on which clini-
cians could base their decision to treat RSV-LRTI patients
with dexamethasone or not. The authors of the report con-
cluded that ‘the results of this trial show that dexamethasone
does not lead to a shorter duration of mechanical ventila-
tion in patients with RSV-LRTI’ (2). Thus their – incorrect
– interpretation was ‘evidence of no effect’.
During the data collection phase of this trial, the results of
another study were published, in which the existence of two
clinically different subgroups of patients with RSV-LRTI was
postulated, based on the extent of gas-exchange anomalies
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during the first hours of admission in the Pediatric Intensive
Care Unit (PICU) (4). Patients were classified as having RSV
bronchiolitis if PaO2/FiO2 > 200 mmHg and/or mean air-
way pressure ≤ 10 cmH2O and as having RSV pneumonia
if PaO2/FiO2 ≤ 200 mmHg and mean airway pressure > 10
cmH2O (5). This led to a post-hoc analysis by Van Woensel
et al. to see whether dexamethasone has a differential effect
in these subgroups (2). The data on arterial blood–gas anal-
ysis could be retrieved in 80 patients. In the bronchiolitis
subgroup (n = 39) a statistically significant and clinically
relevant reduction in days on ventilator was found in favour
of dexamethasone (mean difference 4.3 days; 95% CI 0.8–
7.8 days), whereas in the pneumonia subgroup (n = 41) the
mean difference, although not statistically significant, was in
favour of placebo (difference −0.7 days; 95% CI −3.6 to 2.2
days). The authors found these results difficult to interpret,
and they proposed to do further prospective studies on this
topic.
In the preparation phase of this subsequent research, our
Department of Paediatric Clinical Epidemiology was con-
sulted. One of the questions was whether a triangular test
approach would be more efficient than a fixed sample ap-
proach. In a triangular test the sample size is not fixed at
the start of the trial, but it is derived empirically during the
trial as the amount of information accumulates. The bound-
aries for stopping inclusion of patients in the trial are set in
advance, based on assumptions for α, β and the expected
effect size  , i.e. the minimal clinically relevant difference
divided by its SD (6). These boundaries form a triangle in
a graph defined by V on the X-axis and Z on the Y-axis. V
is a measure of the amount of information gathered so far
and Z is a measure of the effect size. The boundaries are
defined by the formulae Z = a + cV and Z =− a + 3cV.
In case of a double triangular test, in which both possibili-
ties of better and worse outcome of the experimental com-
pared to the control treatment are investigated, two pairs of
boundaries are plotted symmetrically around the horizontal
axis. The boundaries are then also defined by Z =−a −
cV and Z = a − 3cV. This is illustrated in Figures 1 and 2.
The values of Z and V are plotted in this graph after the
outcome of each individual or of a group of patients. The re-
sulting series of dots is called the sample path. Each analysis
leads to a decision either to continue the trial as long as the
sample path is between the boundaries or to stop including
patients when one of the boundaries is crossed. Crossing
of the upper boundary of the single triangular test leads to
the conclusion that the experimental treatment is superior;
crossing of the first part of the lower boundary leads to the
conclusion that the experimental treatment is inferior, cross-
ing of the (dashed) right part of the lower boundary leads to
non-rejection of the null-hypothesis. Crossing of the upper
or lower boundary of the double triangular test leads to the
conclusion that the experimental treatment is superior or in-
ferior, respectively; crossing of the boundaries between both
triangles leads to non-rejection of the null-hypothesis. Each
analysis also leads to adaptation of the boundaries, which
leadstotheso-calledChristmastreeshapeoftheboundaries.
The apex of the triangles designates the maximum value
Figure 1 Double triangular test designed to have 80% power to detect a signif-
icant (two-sided α of 0.05) difference of 1.5 days between the two treatments
assuming a standard deviation of 2 days with the sample path based on in-
spection intervals of ﬁve patients (a) after 11 inspections (n = 55) in the total
patient population; (b) after 7 inspections (n = 35) in the bronchiolitis sub-
group; (c) after 7 inspections (n = 35) in the pneumonia subgroup. Figures (b)
and (c) represent post-hoc analyses without appropriate correction for multiple
testing.
386 C  2008 The Author(s)/Journal Compilation C  2008 Foundation Acta Pædiatrica/Acta Pædiatrica 2009 98, pp. 385–391van der Lee et al. Analysis of paediatric clinical trials
Figure 2 Double triangular test designed to have 80% power to detect a signif-
icant (two-sided α of 0.05) difference of 1.5 days between the two treatments
assuming a standard deviation of 5.3 days with the sample path based on
inspection intervals of ﬁve patients after 16 inspections (n = 80) in the total
patient population.
of V, and thus can be converted into the maximum number
of patients that have to be included in the trial if none of the
boundaries has been crossed before this amount of informa-
tion is assembled (6,7). The computer program PEST can be
used to plot the boundaries and sample path and to calcu-
late the point estimate and its 95% CI (8). If the assumption
for the expected effect size was correct, the power and type
I error rate are maintained throughout this procedure. In a
single triangular test the power to detect superiority of the
experimental treatment is set at a specified percentage; the
power to detect inferiority of the experimental treatment is
much lower.
Considering the challenges posed by this case, we asked
ourselves the following questions:
1. What was the cause for the non-conclusive results in the
first trial?
2. What can be done to prevent non-conclusive results like
this?
3. Could the same results have been obtained more effi-
ciently, i.e. including fewer patients, with a ‘boundaries
approach’?
4. What is the most efficient way to answer the research
question concerning the effectiveness of dexamethasone
in reducing the duration of mechanical ventilation in the
two subgroups of children with RSV bronchiolitis and
RSV pneumonia?
METHODS
To answer the first question, the assumptions used in the
power calculation were compared with the empirically de-
rived data from the trial. If the assumptions were right, there
w a ss t i l lac h a n c eo f2 0 %o fat y p eI Ie r r o r .
The second question is answered by recalculation of the
variance in the former trial and by referring to the literature
about sample size calculations and the conduct of random-
ized clinical trials.
Subsequently, to answer question no. 3, double triangular
tests were performed for the entire study population and for
both subgroups using the raw data from the trial. This was
done first with the assumptions of the trial, then with the
empirical measures of variance.
To answer the fourth question alternative approaches to
study design are considered and their consequences for the
necessary number of patients to be included are estimated.
RESULTS
1. Cause of the non-conclusive results. The only truly un-
certain factor of the assumptions in the power calculation
was the SD of the duration of mechanical ventilation in
days. This was originally assumed to be 2 days, based on
the findings in a subgroup in an earlier, single-centre trial
(9). However, when analysing the data, this was found to be
an underestimate, since the empirical SD in the study pop-
ulation in this multi-centre trial turned out to be 5.3 days.
Application of this value for the SD in the power calculation
would have resulted in a sample size of 196 instead of 30
per intervention group.
Estimations of sample sizes for various design options and
assumptions are shown in Table 1. It might be that the large
variance in the main outcome of the entire study population
was due to differences in the disease subgroups. However,
the empirical SDs were 4.6 and 5.9 days in the pneumonia
and bronchiolitis subgroups, respectively.
An alternative explanation for the large variance in the
duration of mechanical ventilation might have been a dif-
ference in clinical routines between centres involved in this
multi-centre study. No central protocol for extubation was
used. If the mean duration of mechanical ventilation var-
ied between centres irrespective of the treatment, and no
correction for centre was applied, this would increase the
variability of the outcome even if the treatment effect, the
mean difference in duration of ventilations between the dex-
amethasone and placebo groups, was equal in these centres.
That is why the randomization in a multi-centre trial should
always be stratified by centre, and in the analysis adjustment
for centre should be considered. A simulated example of the
application of this principle is given in the Appendix (in
Supporting Information online). Although adjustment for
covariates such as centre effects is generally recommended,
the sensitivity of the estimated effects to covariate adjust-
ment has to be investigated, especially in case of dichoto-
mous or survival outcomes (10,11).
2. Prevention of non-conclusive results. As we have seen,
the main cause of the non-conclusive results was the un-
duly optimistic assumption of variance in the power cal-
culation in the design of the trial. Apart from the possible
explanations mentioned above, i.e. the existence of etiolog-
ical subgroups or the omission of adjusting for centre ef-
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Table 1 Estimated total sample sizes using a ﬁxed sample size design and the triangular test approach in a subsequent clinical trial based on information obtained
in the previous trial
Fixed sample size design Triangular test approach
One-sided type I Two-sided Single triangular test Double triangular test
error (Hypothetical)∗ type I error
Total sample size θ Median∗∗ P90∗∗ Median P90
Without subgroup analysis (SD = 5.3 days) 309 392 θ A 251 407 251 407
θ A /2 265 418 272 418
0 181 315 245 360
−θ A 98 150 251 407
Pneumonia subgroup (SD = 4.6 days) 233 295 θ B 190 307 190 307
θ B /2 200 315 205 315
0 136 237 184 271
−θ B 74 113 190 307
Bronchiolitis subgroup (SD = 5.9 days) 383 486 θ C 312 505 312 505
θ C /2 329 518 337 518
0 224 391 303 446
−θ C 112 186 312 505
A difference of 1.5 days on a ventilator is considered clinically relevant. For the triangular test approach, sample size estimates for four different true effect sizes
(θ) are given. θ A = 1.5/5.3; θ B = 1.5/4.6; θ C = 1.5/5.9.
SD = standard deviation; ∗∗Median and P90 (90th percentile) of expected terminal sample size.
∗A one-sided type I error in comparing dexamethasone with placebo in young children is considered unethical. Data are for illustration only.
Table 2 Issues in the decision to choose either a ﬁxed sample size design or a triangular test approach in a randomized clinical trial
Fixed sample size Triangular test
Risk of biased end result Small if conducted according to well-known standards; if
no interim analyses have been planned, analysis can
be done by investigators after all trial data have been
assembled
Data-analysis should be independent from trial
performance and masked; important that conﬁdentiality
of results is assured until the end of the trial
Feasibility in a multi-centre trial Logistics are known in advance; planning for a speciﬁc
number of trial patients; outcome information may be
assembled per centre and sent to coordinating centre
later
Number of patients to be included unknown at study
onset; planning may be hampered by uncertainties;
block-randomization necessary to avoid discrepancies
in numbers per arm; outcome information has to be
sent to coordinating centre immediately when it occurs
or is measured
Familiarity, acceptance by funders,
editors, peers and readers
Very well-known, generally accepted as the most valid
design to answer questions of effects of interventions
Less familiar design; despite unjust suspicion for
increased risk of type I errors, ﬁnal analysis is valid,
maintaining type I error and power
fects, the SD estimate of 2 days based on a sub-sample of
patients in an earlier study may have been inadequate due to
sampling variation or due to a true difference between pa-
tients and/or interventions in the current and the former
trial (12). However, it may also be due to what is some-
times called the ‘sample size samba’ (13). This term refers
to the process of changing the assumptions of the power
calculation in such a way that it yields a sample size that is
considered desirable or feasible. When we recalculated the
pooled SD for the subgroup of ventilated children in the
first trial by Van Woensel et al. (9), this was shown to be
3.6 days, almost twice the assumption of 2 days used in the
power calculation. Thus it seems that in this case the sam-
ple size samba has at least partly had a hand in the undue
optimism of the sample size calculation of the second trial.
Obviously this could have been prevented by several mea-
sures, of which the most important in our opinion is the cri-
tical review of the design of the trial including the sample
sizecalculationanditsassumptionsbyclinicalandstatistical
experts, either in the phase of review of the grant applica-
tion or, when funding has been assigned, by setting up a data
monitoring committee. If there is insufficient information to
base the assumptions on, an internal pilot study design with
sample size recalculation should be considered (14).
3. Could this result have been obtained more efficiently?
The results of the triangular tests using the original trial’s
assumptions are shown in Figure 1a–c. Assuming an in-
spection interval of five patients, the trial would have been
stopped without rejection of the null-hypothesis after the
analysis of the outcome in 55 patients, resulting in a mean
difference in duration, adjusted for the sequential analysis
of 2.5 days (95% CI −0.6 to 5.8 days). The result would then
be indeterminate – just as in the original trial. However, it
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would have been generated with fewer included patients.
In the bronchiolitis subgroup (Fig. 1b) the triangular test
would have led to continuation of the inclusion beyond the
analysis of 35 patients, probably resulting in rejection of the
null-hypothesis, in favour of dexamethasone. In Figure 1c
the sample path in the pneumonia subgroup can be seen to
cross the middle boundaries, leading to non-rejection of
the null-hypothesis, after analysis of the data from 35 pa-
tients instead of 41 in the original trial. It should be noted
that these post-hoc analyses of the subgroups are merely
intended for illustration to compare with the results of the
originalanalysisandshouldhavebeencorrectedformultiple
testing. When comparing Figures 1b and 1c the subgroups
indeed appear to have a different response to dexametha-
sone, since the sample path almost leads to rejection of the
null-hypothesis after the analysis of 35 patients in the bron-
chiolitis subgroup – and in effect would lead to rejection of
the null-hypothesis after analysis of all 39 patients in this
group, the mean difference being 4.68 [95% CI 0.62–8.68] –
and to non-rejection of the null-hypothesis after analysis of
35 patients in the pneumonia subgroup.
If the empirically found SD of 5.3 days was used to de-
sign the triangular test, it would have looked like the graph
shown in Figure 2. As can be seen from this graph, the sam-
ple path after the analysis of the outcome data from 80 pa-
tients would not even be near one of the boundaries, and
many more patients would have to be included to obtain a
definite result. The theoretical maximum number of patients
to be included, indicated by the right end of the triangle
would be 606, which is considerably more than the number
of 392 resulting from the power calculation for the classic
fixed-sample trial. However, from simulations of trial paths
it can be shown that the median expected number of pa-
tients to be included before crossing one of the boundaries
is 251; the 90th percentile of the expected sample size being
407 (6). The estimated sample sizes for the triangular test in
the subgroups are presented in Table 1. If the true effect size
deviates from the assumptions, the expected sample size in
a triangular test varies accordingly, which means that the
trial will be stopped earlier or later. As an illustration the
medians and P90 of the sample sizes for different true effect
sizes have been included in Table 1.
The triangular test is not the only possible approach to
enhance efficiency in RCTs. Many different statistical ap-
proaches have been developed to enable researchers to take
repeatedlooksattheaccumulatingdatawithoutinflatingthe
pre-specified type I error. The careful evaluation of the result
of such interim analyses by an independent data monitoring
committee may lead to the advice to stop including patients
in the trial, either because the effect of the treatment is larger
than expected, e.g. (15), or because the study, if conducted
until the fixed sample size is attained, will very probably not
lead to rejection of the null-hypothesis, i.e. futility, e.g. (16).
4. How to proceed with this research? The first step in
assessing the evidence on the effect of an intervention is
to assemble all the evidence that is yet available in a sys-
tematic review. If the available evidence is non-conclusive,
i.e. not showing a clear beneficial or detrimental effect or a
fairly narrow CI around the neutral value indicating ‘no ef-
fect’, a new trial should be designed in which the probability
of obtaining definite results that support clinical decision-
making is maximized. All available information about types
of outcome measures and their variance, effects that are con-
sidered clinically relevant and possible subgroups should be
critically evaluated and incorporated in the design of the
new trial. If there is insufficient information about the vari-
ance of an outcome measure in the prospective study popu-
lation, and the number of eligible patients is small, an adap-
tive design can be adopted, containing an internal pilot. This
is an efficient way to optimize the number of patients in a
trial (17,18). An internal pilot can either be used in com-
bination with a classical approach or with a triangular test
design (19). In all instances in which either an internal pilot
or interim analyses are foreseen, an independent data mon-
itoring committee should be set up before the start of the
trial.
In the Cochrane Library a systematic review on the effect
of glucocorticoids for acute viral bronchiolitis in infants and
young children is available (20). However, in this system-
atic review all studies on mechanically ventilated patients
were excluded. Therefore, a systematic review on the effect
of glucocorticoids for acute viral bronchiolitis in ventilated
infants and young children should be done. If the results of
this review show that there is still insufficient evidence to
rule out a detrimental, beneficial or no effect, a new trial
has to be performed in the intensive care setting to generate
sufficient evidence for clinical decision-making. The infor-
mation on variance and effect size derived empirically in the
previoustrialshouldbeusedforthepowercalculationofthis
new trial. Attention should be paid in design and analysis to
possible differences in clinical routines between centres as
shown in the Appendix (in Supporting Information online).
The design should also assure a sufficient sample size and
stratified randomization to perform a subgroup analysis of
the bronchiolitis and pneumonia subgroups using an inter-
action test. The post-hoc subgroup analysis that was done
can only be used for hypothesis-generation (21). Theoret-
ically, for efficiency reasons one-sided hypothesis testing
might be considered if the possibility of inferiority of dexam-
ethasone is very unlikely or if clinicians are only interested
in using dexamethasone if it shows a considerable improve-
ment. This would lead to a considerable reduction of the
fixed sample size as can be seen in Table 1. However, consid-
ering the result in the pneumonia subgroup, and considering
the lack of trust of many clinicians in dexamethasone, in this
particular case two-sided testing would be preferred.
DISCUSSION
In this paper we present a real-life trial case to illustrate the
importance of evaluating the assumptions of a power calcu-
lation. This is a very common problem, even in clinical trials
reported in medical journals of ‘high’ reputation (12). The
estimated number of 60 patients to be included in this trial
resulting from an initial sample size calculation turned out
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to be a gross underestimation of the necessary sample size
of 392 when using the empirically derived variance of the
outcome data, i.e. days on ventilator. Based on data from a
comparable earlier single-centre trial, in which SDs of du-
ration of mechanical ventilation varied between treatment
groups from 2.9 to 4.2 days, the SD of 2 days used in the
power calculation for this more recent trial was found to be
unduly optimistic (9).
A standardized effect size (ratio of clinically relevant dif-
ference and SD) of 0.75 is generally considered to represent
a large treatment effect (22). This should have been con-
sidered beforehand. Moreover, it is not surprising that an
outcome measure, which is predominantly determined by
clinicians, such as duration of mechanical ventilation, varies
more in a multi-centre trial than in a single centre, due to
differences in local clinical routines.
Apart from attempts to explain the unexpected variance
in the trial that served as a case in point, and suggesting
improvement of the analysis by adjusting for centre effects,
we emulated a triangular test design, using the raw data
from the sample trial. This type of design would have yielded
comparable results while including fewer patients.
The decision whether to use a fixed sample design or a tri-
angular test approach to determine the number of patients
that are to be included in a trial depends on the weighing
of several arguments, which cannot be simply solved by a
statistician in a quantitative way. It has been shown in a
series of simulations that the average sample size needed to
complete a trial using a sequential method in simulations
was always smaller than that of the corresponding fixed de-
sign, irrespective of the effect size or power (23). However,
there are several arguments of a cultural nature against the
use of triangular tests. The arguments to decide between a
fixed sample design and a triangular test approach are pre-
sented in Table 2. Apart from the practical and ethical issue
of minimizing the sample size, there are other arguments,
such as the risk of bias, the practical feasibility in a multi-
centre trial, and the familiarity and acceptance of the design
in the international scientific community. In spite of the gen-
eral trend of these ‘qualitative arguments’ to favour the fixed
sample design, the triangular test approach should be con-
sidered when useful evidence is needed for the treatment of
conditions that are rare or occur in patients whose partaking
in research should be minimized such as children. Because
of the vulnerability of children as trial subjects, it is recom-
mended to set up a data safety and monitoring committee
for every paediatric clinical trial, even if no interim analyses
or sequential methods are applied (24).
When considering the necessary sample sizes as shown in
Table 1, some discouragement is imaginable. To co-ordinate
such a large multi-centre trial is quite a challenge. An alter-
native would be to conduct a so-called prospective meta-
analysis, in which each centre conducts a separate ran-
domized clinical trial, including comparable patients and
using identical interventions and outcome measures (25).
This way the technical possibility of pooling the data in a
meta-analysis is assured, without the complicated process
of a centrally led multi-centre trial.
In the present case a subgroup in a previous trial was used
as a pilot for the present trial (9). It would have been more
efficient for either a fixed sample design or a triangular test
to use the data of the first 10 or 20 patients as an internal
pilot to calculate the variance of the outcome measure with-
out de-masking the allocation of the patients. The required
sample size or the boundaries, in case of a fixed sample
design or a triangular test, respectively, can then be estab-
lished without doing any interim analyses (14,17). Since this
was a multi-centre trial, the statistical analysis should have
included investigation of a centre effect and if necessary ad-
justment for this.
RECOMMENDATIONS
Issues of design and analysis of clinical trials are related to a
broad range of expertise, both clinical and statistical. There-
fore we think that clinical investigators should do their best
to obtain critical review of their plans from the very start of
the design phase until publication of the study report, and
evenbeyondthat.Almostallclinicalresearchershavetodeal
with well-known existing review institutions, which are not
always appreciated because of their perceived bureaucracy
and time-consuming procedures, including funding agencies
and their reviewers, institutional review boards and journal
editors and peer reviewers. Nevertheless, critical review and
adviceshouldalsobesoughtfromanindependentdatamon-
itoring committee, both in the design phase and during the
data gathering and analysis, to ensure optimal quality of the
conduct of the trial and minimization of bias and random
error.
CONCLUSION
The design and analysis of the clinical trial featured in this
paper has been shown to suffer from several flaws. Not only
was the original power analysis unduly optimistic but also
the omission of adjustment for centre effects has contributed
to the lack of statistical power. These types of errors are not
uncommon (26). Apart from these methodological issues,
there remains the problem of how to obtain results that can
serve to support clinical decision-making in case of a limited
number of eligible patients.
If eligible patients are scarce, as is the case with chil-
dren mechanically ventilated for RSV, it is important to
make efficient use of all available information. If the inter-
national medical scientific community recognizes the im-
portance of obtaining evidence for the treatment of rare
diseases, often the case in paediatrics, the possible method-
ological alternatives to large randomized clinical trials have
to be explored and taken seriously (27). This recognition
will also have to be earned by researchers in this field con-
ducting and reporting trials in a transparent and method-
ologically sound way, and making maximum use of the
expertise of critical clinicians and statisticians in data mon-
itoring committees.
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